Parohinog, Shermen .
HRN: 22-48-97 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/13/2023
CO-AMOXICLAV 625MG (TAB)
06/13/2023
06/20/2023
PO
625mg
BID
Ovarian New Growth, Right, Prob Malignant Adenoma S/p Right Salpingooophorectomy
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes